Summary
This prediction was cancelled by the user.iBio is a listed biotechnology company with the ticker symbol iBio that focuses on developing novel plant-based biologics and vaccines to combat infectious diseases and other medical conditions. The company leverages its proprietary expression technology to rapidly produce high-quality proteins at a commercial scale, providing a cost-effective and scalable alternative to traditional manufacturing processes. iBio has strategic collaborations with leading pharmaceutical companies and is actively exploring partnerships to advance its product pipeline and expand its reach. The company is headquartered in Bryan, Texas, and is publicly traded on the NYSE American stock exchange.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| iBio Inc. | - | - | - |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% |
Comments by Brookline_Capital_Ma for this prediction
In the thread iBio Inc. diskutieren
iBio, Inc. (NYSE: IBIO) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $3.60 price target on the stock.
Ratings data for IBIO provided by MarketBeat
In the thread Trading iBio Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten